Sign In
Buy RYTM
$99.25
-6.49 (-6.14%)
At Close: Jul 31, 2026
Rhythm Pharma Surges To Record High On 'Impressive' Results In Obesity
11:31am, Wednesday, 09'th Jul 2025
Rhythm Pharmaceuticals shares surged to a record high Wednesday on promising results for a drug that could treat a rare form of obesity.
-- Bivamelagon achieved BMI reductions in patients with acquired hypothalamic obesity of -9.3% and -7.7% in 600mg and 400mg cohorts, respectively, at 14 weeks -- -- Post-hoc analysis showed BMI reduct
BOSTON, July 08, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar
Rhythm Pharmaceuticals: Rare Genetic Obesity Pioneer With Excellent Prospects
11:00am, Monday, 30'th Jun 2025
I maintain my Buy rating on Rhythm Pharmaceuticals due to its leadership in rare genetic obesity treatments. The company's innovative therapies address significant unmet needs, supporting long-term gr
Rhythm Pharmaceuticals Announces Three Late-breaking Data Abstracts Accepted for Presentation at ENDO 2025
08:00am, Wednesday, 25'th Jun 2025
BOSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra
Funds Go All In On Weight-Loss Leader; Stock Nears Highs
12:50pm, Thursday, 29'th May 2025
Rhythm stock is approaching its all-time high in a long base. Rhythm makes drugs to treat disorders due to genetic changes.
-- New data showed setmelanotide achieved consistent, meaningful weight reduction -- -- Multiple presentations delivered at the first-ever Joint Congress between the European Society for Paediatric En
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript
03:21pm, Wednesday, 07'th May 2025
Rhythm Pharmaceuticals, Inc. (RYTM) Q1 2025 Earnings Call Transcript
Rhythm Pharmaceuticals, Inc. (RYTM) Reports Q1 Loss, Lags Revenue Estimates
09:10am, Wednesday, 07'th May 2025
Rhythm Pharmaceuticals, Inc. (RYTM) came out with a quarterly loss of $0.81 per share versus the Zacks Consensus Estimate of a loss of $0.69. This compares to loss of $2.35 per share a year ago.
Rhythm Pharmaceuticals Reports First Quarter 2025 Financial Results and Business Update
07:00am, Wednesday, 07'th May 2025
-- First quarter 2025 net product revenue from global sales of IMCIVREE ® (setmelanotide) of $37.7 million -- -- Setmelanotide pivotal Phase 3 TRANSCEND trial met primary endpoint with -19.8% plac
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
08:00am, Tuesday, 06'th May 2025
BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar
Will Rhythm Pharmaceuticals, Inc. (RYTM) Report Negative Earnings Next Week? What You Should Know
11:06am, Wednesday, 30'th Apr 2025
Rhythm Pharmaceuticals (RYTM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Rhythm Pharmaceuticals (RYTM) Moves 5.2% Higher: Will This Strength Last?
10:40am, Friday, 25'th Apr 2025
Rhythm Pharmaceuticals (RYTM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the
Rhythm Pharmaceuticals to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025
08:00am, Wednesday, 23'rd Apr 2025
BOSTON, April 23, 2025 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with ra
Rhythm: Late-Stage Study Win Brings About Change For Rare Obesity Disorder
01:38pm, Tuesday, 08'th Apr 2025
Rhythm Pharmaceuticals, Inc. met primary endpoint in phase 3 TRANSCEND study, which used setmelanotide for the treatment of patients with acquired hypothalamic obesity. Regulatory submission of setmel
